Although antithrombin, protein C, and protein S defects are well-recognized inherited risk factors for venous thromboembolism (VTE) in adults, whether they predispose children to these vascular disorders as well is undefined. In a prospective cohort study, we assessed the incidence of spontaneous and risk period-related VTE in children who were family members of adults who, after an episode of symptomatic VTE, had then been identified as carriers of these abnormalities. A total of 134 children from 87 families were enrolled. Seventy (51.5%) of these children were carriers of an inherited defect, and the remaining 64 were not; the mean observation period was 4 years (range, 1-16 years) and 3.9 years (range, 1-13), respectively. Sixteen risk periods were experienced by carriers, and 9 by noncarriers. Six VTE occurred in the 70 carriers during 287 observation-years, accounting for an annual incidence of 2.09% patient-years (95% confidence interval, 0.8-4.5), compared with none in the 64 noncarriers during 248 observation-years. Of the 14 children with thrombophilia who experienced a risk period for thrombosis, 4 (28.6%) developed a VTE episode. The overall incidence of risk-related VTE was 25% per risk period (95% confidence interval, 6.8-64). In conclusion, the thrombotic risk in otherwise healthy children with severe inherited thrombophilia does not seem to differ from that reported for adults with the same defects. Screening for thrombophilia in children who belong to families with these defects seems justified to identify those who may benefit from thromboprophylaxis during risk periods for thrombosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656938 | PMC |
http://dx.doi.org/10.1182/bloodadvances.2020002781 | DOI Listing |
Pediatr Infect Dis J
January 2025
Department of Pediatrics, Sections of Hospital Medicine and Emergency Medicine, University of Colorado School of Medicine Aurora, Aurora, Colorado.
Pediatr Infect Dis J
January 2025
Public Health Secretariat, Department of Health, Generalitat de Catalunya, Barcelona, Spain.
Background: In Catalonia, infants <6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyze nirsevimab's effectiveness in hospital-related outcomes of the seasonal cohort (born during the RSV epidemic from October to January 2024) and compared them with the catch-up cohort (born from April to September 2023).
Methods: Retrospective cohort study of all infants born between October 1, 2023, and January 21, 2024, according to their immunization with nirsevimab (immunized and nonimmunized).
Pediatr Infect Dis J
January 2025
From the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Background: The World Health Organization classified coronavirus disease (COVID-19) as a pandemic by March 11, 2020. Children had a milder disease than adults, and many were asymptomatic. The pandemic could be seen as a natural experiment with several changes, including time spent at home.
View Article and Find Full Text PDFPediatr Infect Dis J
January 2025
Cardiovascular Surgery, Gunma Children's Medical Center, Gunma, Japan.
Background: Surgical site infection (SSI) is a significant complication following pediatric cardiovascular surgery. Although drain tip cultures (DTC) are sometimes used postoperatively to predict SSIs, their diagnostic value in pediatric cardiovascular surgery remains unclear. This study aimed to assess the diagnostic utility of DTC for predicting SSIs in pediatric cardiovascular surgery patients.
View Article and Find Full Text PDFPediatr Infect Dis J
January 2025
From the GPIP, Groupe de pathologie infectieuse pédiatrique, Créteil, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!